AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg/24h for 3 days
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroids (methylprednisolone/dexamethasone/prednisone)
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Corticosteroids (methylprednisolone/dexamethasone/prednisone)
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism
Study NCT04380818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism
Study NCT04380818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen supply
Description: Oxygen
Study NCT04380818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen supply
Description: Oxygen
Study NCT01009047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone extended release (ER)
Description: Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
Study NCT01009047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
Study NCT02500485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824, SP2086
Description: One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
Study NCT03137602 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ATOMIC mobile app
Description: (a) PA Coach, One-on-one Chats. Coaches will conduct three one-on-one phone or video conferencing sessions and will also conduct a text messaging session once per week to reinforce and follow-up on the one-on-one phone sessions during the course of the intervention. (b) PA-Self Monitoring. An activity tracker (Fitbit Charge 2) will be used to allow participants to monitor their activity behaviors (e.g. step counts). (c) PA Information. In addition the coach will send weekly tailored PA informational posts/messages aligned with Social Cognitive Theory (SCT) to all participants. (d) Educational Modules. MS specific web-based interactive PA modules will be provided to patients.
Study NCT00651443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galiximab
Description: Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
Study NCT04596787 — intervention group
Intervention type: PROCEDURE
Intervention: Bilateral Thoracic paravertebral block
Description: The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
Study NCT02443103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanabenz acetate
Study NCT01458990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20mg PO BID for 20 days
Study NCT01458990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 20mg PO BID for 20 days
Study NCT04398784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Freeze Dried Blueberry Powder - 71717
Description: Single serve packets containing 22.5 grams of powdered freeze-dried whole blueberries; A mix of 2 species, Vaccinium virgatum (ashei)/Vaccinium corymbosum, provided by U.S Highbush Blueberry Council (USHBC). Powders are sealed in single serve packets to protect from light and moisture. Packets are refrigerated except for when distributed to participants; participants are asked to store packets in refrigerator until consumption.
Study NCT04398784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: USHBC Blueberry Placebo Formula #114
Description: Blueberry flavor- and color-matched placebo powder.
Study NCT02450864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT
Description: Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
Study NCT02450864 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ESWT
Description: Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
Study NCT03173443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single lumen tube and bronchial blocker
Description: fiberoptic intubation with single lumen tube and bronchial blocker
Study NCT03173443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double lumen tube
Description: fiberoptic intubation with double umen tube
Study NCT02878070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calls from a Peer Health Coach for 6 months
Description: Weekly calls for 2 months, bi-weekly calls for 2 months, monthly calls for 2 months.
Study NCT03442166 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LED group
Description: The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
Study NCT03442166 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: Patients will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
Study NCT04520334 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Zhineng Qigong intervention
Description: The intervention consisted of group activities which were performed in one group, as lectures, demonstrations, and Zhineng Qigong training, all planned and led by European Zhineng Qigong.~The group activities were performed during four weekends (12 hours each) and weekly training two times per week (each for two hours). Introductory lecture (two hours) was given at the evening before the first weekend. The respondents were recommended daily Zhineng Qigong training with help of an instructional training CD.
Study NCT01731769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vacuum assisted closure in experimental arm
Study NCT01731769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary dissection
Study NCT01772680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Supplementation
Description: 25 mg elemental zinc taken as zinc sulfate in capsule form taken daily for 3 months
Study NCT03721588 — intervention group
Intervention type: OTHER
Intervention: Clinical interviews, psychometric scales were applied.
Study NCT00849134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1482160 or placebo
Description: GSK1482160 is a P2X7 receptor antagonist
Study NCT00849134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1482160 or placebo
Description: GSK1482160 is a P2X7 receptor antagonist
Study NCT00957749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cPMP
Description: Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
Study NCT06318819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Floss Holders
Description: Dental Floss Holders for flossing purposes
Study NCT06318819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Floss Holders
Description: Dental Floss Holders for flossing purposes
Study NCT00980018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Participants received two 150 \[a total of 300 mg at each dosing\] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules \[a total of 400 mg at each dosing\] for patients enrolled prior to Protocol Amendment 1).
Study NCT01280682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: anti-CD20 monoclonal antibody 125mg/m\^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)
Study NCT01472939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSP-002358 (0.1 mg) + PPI
Description: 0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
Study NCT01472939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSP-002358 (0.5 mg) + PPI
Description: 0.5 mg tablet t.i.d. taken in addition to a PPI
Study NCT03619889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual pressure release technique on trigger points.
Description: A specific pressure is applied on trigger points of masticatory and neck muscles between pain pressure threshold and pain tolerance (7-8 visual analog scale).
Study NCT03619889 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A simulated pressure release technique is applied around masticatory and neck muscles.
Study NCT05251857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients
Description: Behavioral: Animation Education Program The investigators will apply Animation Education Program.
Study NCT03371537 — intervention group
Intervention type: PROCEDURE
Intervention: Liver debit measure
Description: Mesure of liver debit during hepatectomy
Study NCT00536081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: 6 mg s.c. 24-36 h post-chemotherapy
Study NCT00536081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg s.c. 24-36 h post-chemotherapy
Study NCT02999932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SpO2 directed oxygen therapy
Description: Oxygen therapy was administered to achieve targeted SpO2.
Study NCT02999932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SpO2 directed oxygen therapy
Description: Oxygen therapy was administered to achieve targeted SpO2.
Study NCT03577756 — intervention group
Intervention type: OTHER
Intervention: Neurodevelopmental assessments
Description: Infants' neurodevelopmental assessments will be done by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. Bayley-III assess the development of five distinct scales to be consistent with areas of appropriate developmental assessment for children from birth to age 3. The Bayley-III revision includes Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales.The Gross Motor Function Measure (GMFM) has 5 dimensions: A-lying and roll- ing; B-sitting; C- kneeling and crawl- ing; D-standing; and E-walking, run- ning, and jumping. The items are scored from 0 to 3. All items are summarized and expressed as a value of total points for each dimension of the GMFM.
Study NCT02705625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIV-711
Description: MIV-711 administered orally once daily
Study NCT02705625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo manufactured to mimic MIV-711 capsule.
Study NCT00329550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
Study NCT00329550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
Study NCT00329550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
Study NCT02205047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02205047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02205047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil or Capecitabine
Study NCT02205047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil or Capecitabine
Study NCT02205047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT02205047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Study NCT02205047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrectomy
Description: D2 gastrectomy
Study NCT02205047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastrectomy
Description: D2 gastrectomy
Study NCT02072798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
Study NCT01628289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: charging a co-payment for Diabetic Retinopathy screening
Description: The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
Study NCT01628289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: free screening without charging a co-payment
Description: The intervention is to provide free screening without charging a co-payment
Study NCT01871168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Infusion of 0.5-1% lidocaine
Study NCT01871168 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham TAP block
Description: Infusion of saline
Study NCT03820570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hernia repair
Description: inguinal hernia repair
Study NCT04561583 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LED light source system for endoscope
Description: This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period.
Study NCT04561583 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pinpoint Endoscopic Fluorescence Imaging System
Description: This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period.
Study NCT03978078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: - Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
Study NCT02145897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stromal Vascular Fraction (SVF)
Description: Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
Study NCT02145897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Derieved MSCs
Description: Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
Study NCT02145897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT00875615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
Study NCT00875615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
Study NCT00875615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
Study NCT02352077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffold with BMMCs or MSCs transplantation
Description: Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
Study NCT03730662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.
Study NCT03730662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study NCT01472939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSP-002358 (2.0 mg) + PPI
Description: 2.0 mg tablet t.i.d. taken in addition to a PPI
Study NCT01472939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + PPI
Description: Placebo t.i.d. taken in addition to a PPI
Study NCT00664703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeline sulfate
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Study NCT00664703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate HCl
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Study NCT00664703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Study NCT02843958 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HEMOPTIC